Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Sanofi, CVS Health, Others Accused of Insulin Price Fixing

March 20, 2017, 9:48 PM

The leading U.S. drugmakers and pharmacy benefit managers colluded to fix prices for insulin, leading to skyrocketing costs and windfall profits for the companies, a new lawsuit alleges (Boss v. CVS Health Corp., D.N.J., No. 2:17-cv-01823, complaint filed 3/17/17).

Some of the biggest players in the American health-care industry are targeted in the 69-count class action complaint, filed March 17 in a federal court in New Jersey. Drug manufacturers Sanofi-Aventis, Novo Nordisk and Eli Lilly are included. Also named are the country’s three largest pharmacy benefit managers—CVS Health, Express Scripts and OptumRx—which together control 80 percent of the ...